Benign fibrous histiocytoma

Summary

Benign fibrous histiocytoma (MONDO:0002989) is a disease and 2 clinical trials. Top therapeutic interventions include bevacizumab. A subtype of histiocytoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	benign fibrous histiocytoma
Mondo ID	MONDO:0002989
MeSH	D018219
DOID	DOID:4415
ICD-11	476723055
NCIT	C3739
UMLS	C0206644
MedGen	60199
Is cancer (heuristic)	no

Also known as: benign fibrous histiocytoma · benign fibrous histiocytoma (morphologic abnormality) · fibrous histiocytoma · fibrous histiocytoma NOS (morphologic abnormality) · fibroxanthoma NOS (morphologic abnormality) · histiocytoma, fibrous, benign

Data availability: 1 cell line.

Disease family

This is a subtype of histiocytoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › histiocytoma › benign fibrous histiocytoma

Related subtypes (2): undifferentiated pleomorphic sarcoma, histiocytoma, Angiomatoid fibrous

Subtypes (2): benign deep fibrous histiocytoma, cutaneous fibrous histiocytoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Bevacizumab.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00356031	PHASE2	COMPLETED	Bevacizumab and Radiation Therapy for Sarcomas
NCT06387485	Not specified	RECRUITING	A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BEVACIZUMAB	4	1